
Neogen Corporation NEOG
$ 9.45
-0.94%
Quarterly report 2026-Q1
added 04-09-2026
Neogen Corporation Book Value 2011-2026 | NEOG
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.07 B | 3.14 B | 3.13 B | 887 M | 840 M | 725 M | 638 M | 560 M | 472 M | 404 M | 351 M | 306 M | 258 M | 219 M | 189 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.14 B | 189 M | 947 M |
Quarterly Book Value Neogen Corporation
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.1 B | 2.1 B | 2.12 B | 2.07 B | 2.66 B | 2.67 B | 3.14 B | 3.14 B | 3.15 B | 3.15 B | 3.15 B | 3.13 B | 3.13 B | 3.11 B | 884 M | 887 M | 876 M | 867 M | 855 M | 840 M | 840 M | 777 M | 752 M | 774 M | 712 M | 691 M | 660 M | 693 M | 663 M | 602 M | 582 M | 603 M | 583 M | 521 M | 487 M | 524 M | 491 M | 435 M | 417 M | 442 M | 421 M | 378 M | 366 M | 385 M | 368 M | 327 M | 319 M | 327 M | 319 M | 282 M | 271 M | 287 M | 276 M | 238 M | 229 M | 237 M | 228 M | 203 M | 197 M | 204 M | 197 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.15 B | 197 M | 1.02 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 115.62 | 0.06 % | $ 35.1 B | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Illumina
ILMN
|
6.3 B | $ 128.52 | 0.5 % | $ 20.4 B | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 1.65 | -1.2 % | $ 2.19 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 84.11 | -0.26 % | $ 5.68 B | ||
|
Medpace Holdings
MEDP
|
459 M | $ 421.37 | 2.64 % | $ 12.2 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 24.98 | 2.13 % | $ 694 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.54 | 0.25 % | $ 20 B | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Personalis
PSNL
|
203 M | $ 5.96 | -2.3 % | $ 353 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 21.85 | 2.92 % | $ 1.16 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Senseonics Holdings
SENS
|
61 M | $ 7.27 | 3.12 % | $ 303 M | ||
|
Soleno Therapeutics
SLNO
|
450 M | $ 52.75 | 0.06 % | $ 2.68 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 15.6 | -4.35 % | $ 472 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 468.04 | -0.36 % | $ 176 B | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.64 | -0.82 % | $ 61.9 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 171.23 | 0.86 % | $ 8.49 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 61.0 | 0.1 % | $ 3.65 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 88.5 | -0.46 % | $ 11.1 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
22.4 M | - | - | $ 8.54 M | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.18 | 1.87 % | $ 5.01 M | ||
|
National Research Corporation
NRC
|
14 M | $ 17.11 | -0.7 % | $ 383 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 103.21 | 1.02 % | $ 8.51 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.43 | -0.14 % | $ 21.9 B | ||
|
Celcuity
CELC
|
101 M | $ 125.68 | 3.84 % | $ 5.88 B | ||
|
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.61 | 3.86 % | $ 1.1 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.83 | 1.05 % | $ 447 M | ||
|
Natera
NTRA
|
706 M | $ 204.46 | 0.35 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 196.63 | 0.18 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M |